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Background: Adjunctive Cilostazol (Pletaal®) to dual antiplatelet therapy (triple antiplatelet) is known to reduce restenosis and associated 
with favorable clinical outcomes in selective group of patients (pts). However, the efficacy and safety of triple antiplatelet therapy in all comers 
undergoing percutaneous coronary intervention (PCI) with drug-eluting stent (DES) in real-world clinical practice is unclear.
Methods: The study population consisted of 1,689 consecutive pts who underwent PCI with DES. Cilostazol was administered by 200mg post-
loading and then 100mg bid for at least one month.
Results: Out of 1689 enrolled pts, 659 pts (39.02%) received Triple and 1030 pts (60.98%) Dual therapy. Pts with Cilostazol group had more male 
(69.8% vs. 64.1%, P=0.015), worse baseline angiographic characteristics including more bifurcation (34.6% vs. 28.9 %, P=0.001), left main (7.9% 
vs. 2.3%, P<0.001), diffuse long (34.1% vs. 26.8%, P=0.001) and Ostial Lesions (19.9% vs. 13.9%, P=0.001). Despite the higher risk subset of pts 
in Cilostazol group, major clinical hard endpoints, incidence of stent thrombosis and angiographic outcomes were similar between the two groups 
(Table).
Conclusion: Triple antiplatelet therapy including adjunctive Cilostazol in high risk pts undergoing PCI with DES in real world clinical practice 
showed similar midterm clinical and angiographic outcomes compared with those of usual pts with dual antiplatelet therapy.
Table. 6-month Clinical and Angiographic Outcomes 
Variables, N (%) No Cilostazol Group (N=1030 pts) Cilostazol Group (N=659 pts) P-Value OR (95%CI)
Death 31 (3.0) 22 (3.3) 0.213 0.52 (0.19-1.43)
MI 7 (0.7) 8 (1.2) 0.625 1.41 (0.36-5.48)
TLR 43 (4.2) 29 (4.4) 0.714 1.11 (0.64-1.94)
TVR 50 (4.9) 37 (5.6) 0.974 0.99 (0.60-1.65)
MACE 78 (7.6) 56 (8.5) 0.791 0.94 (0.59-1.50)
Stent Thrombosis 12 (1.1) 5 (0.9) 0.189
Subacute (1-30 day) 3 (0.3) 5 (0.8)
Late (30 day-6 months) 9 (0.9) 0 (0.0)
Binary Restenosis 82 (8.9) 57 (9.6) 0.899 1.03 (0.68-1.55)
Restenosis % 24.54±21.41 24.30±23.62 0.880 ----
Late Loss 0.82±0.68 0.88±0.74 0.190 ----
